LAWRENCE CHIN CHAN, MD
Osteopathic Medicine at Main St, Houston, TX
License number
Texas E3158
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
6620 Main St SUITE 1225, Houston, TX 77030
Phone
(713) 798-2500
(713) 798-4478
(713) 798-4478
Personal information
See more information about LAWRENCE CHIN CHAN at radaris.comName
Address
Phone
41 Hackberry Ln, Houston, TX 77027
4500 Cypresswood Dr, Spring, TX 77379
6636 W William Cannon Dr, Austin, TX 78735
7 Switchbud Pl STE 190, Spring, TX 77380
1805 Peek Dr, Plano, TX 75075
Professional information
Lawrence Chinbong Chan, Houston TX
Specialties:
Endocrinologist
Address:
1 Baylor Plz, Houston, TX 77030
Education:
University of Hong Kong - Doctor of Science
University of Hong Kong, Li Ka Shing Faculty of Medicine - Bachelor of Medicine, Bachelor of Surgery
Barnes-Jewish Hospital - Residency - Internal Medicine
University of Hong Kong, Li Ka Shing Faculty of Medicine - Bachelor of Medicine, Bachelor of Surgery
Barnes-Jewish Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
President At Houston Discovery Community Llc
Position:
President at Houston Discovery Community LLC
Location:
Houston, Texas Area
Industry:
Hospital & Health Care
Work:
Houston Discovery Community LLC
-
President
Lawrence Chin Bong Chan, Houston TX
Specialties:
Internal Medicine, Endocrinology, Diabetes & Metabolism
Work:
One Baylor Plaza
1 Baylor Plz, Houston, TX 77030
1 Baylor Plz, Houston, TX 77030
Education:
University Of Hong Kong (1966)
Lawrence C Chan
Hospitals:
BCM Endocrinology Section of IM
1 Baylor Plz, Houston 77030
BAYLOR COLLEGE OF MEDICINE
6620 Flr SUITE 12TH, Houston 77030
St. Luke's Medical Center
6720 Bertner Ave, Houston 77030
BCM Endocrinology Section of IM
1 Baylor Plz, Houston 77030
BAYLOR COLLEGE OF MEDICINE
6620 Flr SUITE 12TH, Houston 77030
St. Luke's Medical Center
6720 Bertner Ave, Houston 77030
1 Baylor Plz, Houston 77030
BAYLOR COLLEGE OF MEDICINE
6620 Flr SUITE 12TH, Houston 77030
St. Luke's Medical Center
6720 Bertner Ave, Houston 77030
BCM Endocrinology Section of IM
1 Baylor Plz, Houston 77030
BAYLOR COLLEGE OF MEDICINE
6620 Flr SUITE 12TH, Houston 77030
St. Luke's Medical Center
6720 Bertner Ave, Houston 77030
Education:
Medical Schools
U Hong Kong
University of Hong Kong Li Ka Shing Faculty of Medicine
U Hong Kong
University of Hong Kong Li Ka Shing Faculty of Medicine
Peptides That Target Dorsal Root Ganglion Neurons
US Patent:
2011018, Aug 4, 2011
Filed:
Jan 30, 2009
Appl. No.:
12/864895
Inventors:
Lawrence Chan - Houston TX, US
Hideto Kojima - Houston TX, US
Tomoya Terashima - Houston TX, US
Hideto Kojima - Houston TX, US
Tomoya Terashima - Houston TX, US
Assignee:
BAYLOR COLLEGE OF MEDICINE - Houston TX
International Classification:
A61K 9/127, C07K 7/06, A61K 38/08, C07K 19/00, A61K 35/76, A61K 38/20, C07H 21/00, A61P 25/00, A61P 35/00, A61P 31/00, A61P 3/00
US Classification:
424450, 530329, 514 217, 424 936, 424 852, 514 177, 536 234
Abstract:
The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.
Induction Of Pancreatic Islet Formation
US Patent:
2004013, Jul 8, 2004
Filed:
Sep 3, 2003
Appl. No.:
10/654102
Inventors:
Lawrence Chan - Houston TX, US
Hideto Kojima - Houston TX, US
Hideto Kojima - Houston TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
A61K048/00, A61K038/18
US Classification:
514/044000, 514/012000
Abstract:
The present invention is directed to compositions of an islet cell differentiation transcription factor polypeptide, or any of its homologs or orthologs, as a therapeutic agent for the treatment of diabetes, more specifically insulin-dependent diabetes. The methods and compositions of the present invention provide an increase in glucose tolerance, an increase in insulin, and/or an increase in insulin-producing cells in the host.